NCT02723084View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus Infection

PHASE3CompletedINTERVENTIONAL
Enrollment

136

Participants

Timeline

Start Date

April 8, 2016

Primary Completion Date

January 19, 2017

Study Completion Date

March 24, 2017

Conditions
Chronic Hepatitis C VirusHepatitis C Virus
Interventions
DRUG

ABT-493/ABT-530

Co-formulated tablet

DRUG

sofosbuvir (SOF)

Tablet

DRUG

ribavirin (RBV)

Capsule

Sponsors

Lead Sponsor

AbbVie
All Listed Sponsors
lead

AbbVie

INDUSTRY